obesity, Novo Nordisk

Novo Nordisk posts Q3 sales of obesity drug Wegovy above forecast
Novo Nordisk on Wednesday reported better-than-expected quarterly sales of its popular Wegovy weight-loss drug and narrowed its 2024 outlook for the year, in a mixed set of results reflecting growing competition in the fast-growing obesity drug market.
Lilly shares fall as obesity drug sales miss forecasts
Third quarter Mounjaro and Zepbound sales, while up substantially versus the same period last year, grew little compared to the second quarter as wholesalers bought less supply.
Novo Nordisk reports continued growth in obesity drug sales
Novo Nordisk shares were up Wednesday following an earnings report that showed continued sales growth of its obesity drug.
Lilly Cuts Outlook After Obesity Drug Sales Post First Miss
Eli Lilly & Co. lowered its full-year guidance Wednesday after sales of its blockbuster weight-loss drug fell short of expectations, which the company blamed on inventory issues.Most Read from Bloombe
Novo Nordisk maintains booming sales of obesity and diabetes drugs
The Danish company’s share price rise of 7 per cent this year lags far behind its rival Eli Lilly’s 36 per cent, as the US company has gradually increased its share of the obesity and diabetes market and Novo Nordisk has faced lower prescriptions of Wegovy than expected.
Novo Nordisk's Wegovy weight-loss drug sales beat forecast, shares jump
Novo Nordisk reported on Wednesday better-than-expected quarterly sales of its popular Wegovy weight-loss drug, reassuring investors worried the drugmaker was losing its lead in the fast-growing obesity drug market to U.
Novo Nordisk’s Wegovy Sales Surge on Crucial US Market
Novo Nordisk A/S’s sales of the blockbuster weight-loss drug Wegovy leapt in the third quarter, a potential relief for investors after rival Eli Lilly & Co. reported disappointing obesity sales last week.
Shares in weight-loss drugmaker Eli Lilly fall on disappointing sales
Weight-loss drugmaker Eli Lilly delivered lower sales and earnings per share than expected in the third quarter, blaming high manufacturing costs and fluctuating inventory levels as it races to keep up with soaring demand for its blockbuster anti-obesity treatments.
Americans seeking Eli Lilly and Novo Nordisk’s weight-loss drugs turn to compounded market
An injection pen of Zepbound, Eli Lilly’s weight-loss drug ... Lilly last week reported a rare $1.5 billion sales ...
Viking Therapeutics soars as early-stage oral obesity drug data exceeds expectations
Viking Therapeutics shares surged 25% before the bell on Monday after early-stage data from the company's experimental oral ...
Why Eli Lilly Is a No-Brainer Stock to Buy on the Dip
Here's why Eli Lilly is a no-brainer stock to buy on the dip ... Q3 earnings call that wholesalers decreased their ...
Mounjaro's Sales Likely To Rise 2.5x Driving Eli Lilly's Q3 Performance
The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the ...
stocknews13d
Is Eli Lilly Still a Top Healthcare Stock After Its Blockbuster Drug Approval?
Pharmaceutical giant Eli Lilly and Company (LLY) is on an impressive run after winning Food and Drug Administration approval ...
Billionaire Stanley Druckenmiller Closed Out His Position in Eli Lilly Stock. 3 Reasons Why I'm Still a Buyer.
Eli Lilly stock has soared on a new growth wave driven by its diabetes and obesity care treatments. While this has made profit-taking in Lilly stock tempting, the company has several catalysts ahead.
As Race To Best 'Miracle' Obesity Drug Heats Up, Ozempic Maker Novo Nordisk Tests New Hybrid Drug That Can Reduce Weight Up To 25%
Novo's development chief, Martin Holst Lange, has shown optimism about the drug's promise, though he refrained from making ...
What You May Have Missed From Eli Lilly's Q3 2024 Earnings Disappointment
LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...